National Health Investors Inc is a US-listed company in the health care REITs industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$91
Valuation models combined (2)
Base case. Range ~$75–$100. Weighted average of 2 models (funds-from-operations model, dividend discount (growing dividend)), the funds-from-operations model counting double.
No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.
National Health Investors Inc valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $432m, up 23.9% on a year earlier, faster than the 17.1% growth a quarter earlier. The diluted share count is up 5.7% on a year earlier, which dilutes existing holders.
Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
National Health Investors Inc's trailing-twelve-month revenue grew 23.9% year on year, with a free-cash-flow margin of 36.5%. Where it stands out: change in growth rate of +6.9pp ranks 2 of 17 health care reits companies we cover.
Current signal Revenue growth accelerating: TTM revenue growth rose to 23.9% (+6.9pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value National Health Investors Inc as an equity reit, with every model that fits that kind of business. Cost of equity 7.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.56 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Funds-from-operations model Funds from operations growing 2.5% a year, discounted at 8%. | ~$100 ~$84–$120 | Primary model, counts double |
| Price-to-FFO vs peers Funds from operations per share times peers' typical (harmonic-mean) price-to-FFO. | ~$1.9 ~$45–$93 | Left out: out of range vs price (0.03x) |
| Dividend discount (growing dividend) Today's dividend growing 2.5% a year, discounted at the cost of equity. | ~$75 ~$63–$94 | Included |
| Combined value Weighted average of the models that apply: the primary model (funds-from-operations model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$91 ~$75–$100 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare National Health Investors Inc with equity REITs in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Strong moat
How hard National Health Investors's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Net income has been a median 5.2% of total assets over 10 years.
Operating margin has been a median 78.1%; its worst year was 58.1%.
Free cash flow was positive in 9 of 10 years, at a median 37.9% of revenue.
The diluted share count rose 6.5% over five years; stock-based pay has been a median 1.4% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Next results: November 9, 2026, after the close. Analysts expect revenue of $112m for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $4.05 | +34% | $457m | +22% |
| Next | $3.45 | — | $488m | +7% |
Next year's EPS estimate has moved +4.2% in 90 days, across 1 analysts.
The consensus EPS forecast for the current fiscal year is +7.7% on 90 days ago. In the last 30 days, 1 analyst raised National Health Investors Inc's forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $3.77 | $3.31 |
| 60 days ago | $4.19 | $3.25 |
| 30 days ago | $3.89 | $3.25 |
| 7 days ago | $4.05 | $3.35 |
| Now | $4.05 | $3.45 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $4.57 | $1.15 | −74.8% |
| Mar 2026 | $0.86 | $0.77 | −10.5% |
| Dec 2025 | $0.80 | $0.76 | −5.2% |
| Sept 2025 | $0.60 | $0.69 | +14.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months −3.4%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $349m | $432m | +23.9% |
| Net margin | 41.0% | 38.6% | −5.8% |
| P/E multiple | 22.6x | 19.8x | −12.5% |
| Share count | 46m | 48m | −5.4% |
Biggest factor: revenue.
Last 3 years +55.3%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $307m | $432m | +40.6% |
| Net margin | 36.0% | 38.6% | +7.2% |
| P/E multiple | 17.4x | 19.8x | +13.7% |
| Share count | 44m | 48m | −9.4% |
Biggest factor: revenue.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| NHI | −12% | −3% | +15% | +31% | +16% | −7% |
| Industry peers (median) | +6% | −21% | +2% | +12% | +26% | +13% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| NHI | 58% | 58% | 58% | 67% | 50% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| NHI | −32% | −23% | −19% | −18% | −9% | −27% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 63% from February 21, 2020 to March 18, 2020. Getting back needed a 171% gain, reached on June 28, 2024, 1563 days after the low.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 10, 2026 | −7.1% | −0.3% | −2.5% | −6.8% |
| May 4, 2026 | −4.7% | +0.4% | −4.3% | −9.3% |
| February 26, 2026 | −4.6% | −1.0% | −4.6% | −6.7% |
| November 6, 2025 | +0.8% | −1.0% | +0.9% | +3.5% |
| August 6, 2025 | +1.7% | +0.7% | +1.6% | +7.0% |
| May 5, 2025 | +0.6% | −1.4% | −0.4% | −6.4% |
| February 25, 2025 | +0.7% | −0.4% | +3.2% | +4.8% |
| November 5, 2024 | +1.1% | +3.7% | +5.7% | −0.4% |
| August 6, 2024 | +3.0% | +0.2% | +2.7% | +13.8% |
| May 6, 2024 | +1.4% | +1.1% | +1.8% | +2.8% |
| February 20, 2024 | +6.6% | −0.5% | +10.5% | +14.6% |
| November 7, 2023 | +0.5% | +0.4% | +4.9% | +7.8% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $311M |
| FY23 Q4 | $319.8M |
| FY24 Q1 | $319M |
| FY24 Q2 | $326.1M |
| FY24 Q3 | $328.9M |
| FY24 Q4 | $335.2M |
| FY25 Q1 | $343M |
| FY25 Q2 | $348.7M |
| FY25 Q3 | $355.6M |
| FY25 Q4 | $375.6M |
| FY26 Q1 | $401.5M |
| FY26 Q2 | $432.1M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 12.2% |
| FY23 Q4 | 15.0% |
| FY24 Q1 | 10.3% |
| FY24 Q2 | 6.1% |
| FY24 Q3 | 5.7% |
| FY24 Q4 | 4.8% |
| FY25 Q1 | 7.5% |
| FY25 Q2 | 6.9% |
| FY25 Q3 | 8.1% |
| FY25 Q4 | 12.1% |
| FY26 Q1 | 17.1% |
| FY26 Q2 | 23.9% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY12 Q1 | 78.9% |
| FY12 Q2 | 70.2% |
| FY12 Q3 | 63.7% |
| FY12 Q4 | 78.1% |
| FY13 Q1 | 71.8% |
| FY13 Q2 | 70.0% |
| FY13 Q3 | 73.5% |
| FY13 Q4 | 67.5% |
| FY14 Q1 | 66.6% |
| FY14 Q2 | 63.8% |
| FY14 Q3 | 60.4% |
| FY14 Q4 | 58.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | 34.5% |
| FY23 Q4 | 35.8% |
| FY24 Q1 | 39.0% |
| FY24 Q2 | 41.4% |
| FY24 Q3 | 40.6% |
| FY24 Q4 | 40.7% |
| FY25 Q1 | 40.9% |
| FY25 Q2 | 39.3% |
| FY25 Q3 | 41.7% |
| FY25 Q4 | 41.4% |
| FY26 Q1 | 39.4% |
| FY26 Q2 | 36.5% |
| Fiscal year | 2009 Dec 2009 | 2010 Dec 2010 | 2011 Dec 2011 | 2012 Dec 2012 | 2013 Dec 2013 | 2014 Dec 2014 | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||||
| Revenue | 63 | 83 | 84 | 93 | 118 | 178 | 229 | 248 | 279 | 295 | 318 | 333 | 299 | 278 | 320 | 335 | 376 | 432 |
| EBITDA | — | — | — | — | — | 141 | 203 | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | 49 | 62 | 70 | 73 | 79 | 103 | 150 | — | — | — | — | — | — | — | — | — | — | — |
| Net income | 64 | 69 | 81 | 91 | 106 | 102 | 149 | 152 | 159 | 154 | 160 | 185 | 112 | 66 | 136 | 138 | 142 | 167 |
| Diluted EPS | $2.32 | $2.50 | $2.92 | $3.26 | $3.74 | $3.04 | $3.95 | $3.87 | $3.87 | $3.67 | $3.67 | $4.14 | $2.44 | $1.48 | $3.13 | $3.13 | $3.02 | $3.46 |
| Growth (year on year) | ||||||||||||||||||
| Revenue | +10.3% | +31.5% | +1.4% | +11.4% | +26.3% | +50.7% | +29.0% | +8.5% | +12.2% | +5.7% | +8.0% | +4.6% | −10.2% | −6.9% | +15.0% | +4.8% | +12.1% | +23.9% |
| EBITDA | — | — | — | — | — | — | +44.1% | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | +9.0% | +27.0% | +13.0% | +4.3% | +9.1% | +29.6% | +45.9% | — | — | — | — | — | — | — | — | — | — | — |
| Net income | +11.7% | +8.1% | +16.9% | +11.8% | +17.0% | −4.3% | +46.5% | +1.8% | +5.2% | −3.2% | +4.0% | +15.4% | −39.6% | −40.6% | +104.3% | +1.7% | +3.0% | +16.7% |
| Diluted EPS | +12.1% | +7.8% | +16.8% | +11.6% | +14.7% | −18.7% | +29.9% | −2.0% | 0.0% | −5.2% | 0.0% | +12.8% | −41.1% | −39.3% | +111.5% | 0.0% | −3.5% | +10.4% |
| Margins | ||||||||||||||||||
| EBITDA margin | — | — | — | — | — | 79.5% | 88.9% | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 77.5% | 74.8% | 83.4% | 78.1% | 67.5% | 58.1% | 65.7% | — | — | — | — | — | — | — | — | — | — | — |
| Net margin | 102.3% | 84.1% | 96.9% | 97.2% | 90.1% | 57.2% | 65.0% | 61.0% | 57.2% | 52.4% | 50.4% | 55.6% | 37.4% | 23.9% | 42.4% | 41.2% | 37.9% | 38.6% |
| Free-cash-flow margin | — | −25.7% | 1.3% | −26.1% | −467.2% | −229.3% | 17.6% | −87.8% | 8.0% | 20.4% | 1.2% | 34.7% | 53.7% | 62.7% | 42.2% | 14.9% | −15.3% | 57.5% |
| Cash flow | ||||||||||||||||||
| Cash from operations | 69 | 78 | 77 | 86 | 104 | 126 | 164 | 177 | 198 | 208 | 241 | 232 | 211 | 185 | 184 | 208 | 237 | 249 |
| Capital spending | — | 99 | 76 | 111 | 655 | 533 | 124 | 395 | 176 | 148 | 237 | 117 | 50 | 11 | 50 | 158 | 294 | 0 |
| Free cash flow | — | −21 | 1 | −24 | −550 | −407 | 40 | −218 | 22 | 60 | 4 | 115 | 161 | 174 | 135 | 50 | −57 | 249 |
| Stock-based pay | 1 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 4 | 5 | 5 | 9 | 5 | 4 | 6 | 7 |
| Free cash flow after stock pay | — | −24 | −2 | −27 | −553 | −409 | 38 | −220 | 20 | 58 | 0 | 110 | 155 | 166 | 130 | 46 | −63 | 242 |
| Balance sheet | ||||||||||||||||||
| Cash | 46 | 3 | 16 | 9 | 11 | 3 | 13 | 5 | 3 | 5 | 5 | 43 | 37 | 19 | 22 | 24 | 20 | 30 |
| Total debt | 0 | 0 | 97 | 203 | 617 | 863 | 934 | 1,132 | 1,160 | 1,294 | 1,449 | 1,503 | 1,249 | 1,159 | 1,146 | 1,157 | 1,179 | 1,288 |
| Net debt (negative = net cash) | −46 | −3 | 81 | 194 | 606 | 860 | 921 | 1,127 | 1,157 | 1,290 | 1,444 | 1,460 | 1,212 | 1,139 | 1,124 | 1,133 | 1,159 | 1,258 |
| Diluted shares | 28m | 28m | 28m | 28m | 28m | 33m | 38m | 39m | 41m | 42m | 44m | 45m | 46m | 45m | 43m | 44m | 47m | 48m |
| Returned to shareholders | ||||||||||||||||||
| Dividends | 65 | 67 | 68 | 79 | 85 | 101 | 125 | 138 | 153 | 165 | 180 | 195 | 183 | 162 | 156 | 157 | 170 | 176 |
| Buybacks | 0 | 0 | — | — | — | — | — | — | — | — | — | 0 | 0 | 152 | 0 | 0 | — | — |
| Total returned | 65 | 67 | 68 | 79 | 85 | 101 | 125 | 138 | 153 | 165 | 180 | 195 | 183 | 314 | 156 | 157 | 170 | 176 |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 83 | 86 | 89 | 91 | 90 | 106 | 115 | 121 |
| Net income | 29 | 43 | 34 | 37 | 33 | 38 | 40 | 56 |
| Diluted EPS | $0.65 | $0.96 | $0.74 | $0.79 | $0.69 | $0.80 | $0.82 | $1.15 |
| Growth (year on year) | ||||||||
| Revenue | +3.5% | +7.9% | +9.5% | +6.7% | +8.3% | +23.4% | +28.9% | +33.8% |
| Net income | −2.7% | +34.9% | +10.4% | +4.9% | +15.1% | −11.7% | +17.4% | +50.5% |
| Diluted EPS | −4.4% | +29.7% | +4.2% | −2.5% | +6.2% | −16.7% | +10.8% | +45.6% |
| Margins | ||||||||
| Net margin | 34.4% | 50.4% | 38.3% | 40.8% | 36.6% | 36.1% | 34.8% | 45.9% |
| Free-cash-flow margin | — | −62.1% | −43.3% | — | — | −71.4% | −48.6% | — |
| Cash flow | ||||||||
| Cash from operations | 49 | 58 | 46 | 60 | 63 | 68 | 53 | 65 |
| Capital spending | — | 111 | 85 | — | — | 143 | 109 | — |
| Free cash flow | — | −53 | −39 | — | — | −76 | −56 | — |
| Stock-based pay | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 2 |
| Free cash flow after stock pay | — | −54 | −41 | — | — | −77 | −58 | — |
| Last 12 months unless stated | NHI | DEA | LTC | NHP | CTRE | SBRA | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $432m | $365m | $348m | $344m | $571m | $919m | $919m |
| Revenue growth, last 12 months | 23.9% | 11.4% | 59.8% | −1.2% | 53.0% | 23.4% | 15.0% |
| Revenue growth, 3-year average | 12.0% | 8.2% | 22.5% | 0.2% | 40.9% | 12.3% | 12.0% |
| Revenue growth, latest quarter | 33.8% | 8.7% | 64.1% | 2.6% | 43.5% | 31.3% | 11.1% |
| Gross margin | — | 77.2% | — | 37.9% | 100.0% | — | 60.1% |
| Operating margin | 58.1% | 19.7% | 62.6% | 3.2% | — | — | 35.3% |
| Operating margin, 3-year average | 67.9% | 15.9% | 83.2% | −10.7% | — | — | 35.7% |
| Net margin | 38.6% | 4.0% | 38.9% | −16.7% | 62.2% | 7.8% | 7.8% |
| Cash from operations / revenue | 57.5% | 44.2% | 40.7% | 14.7% | 78.2% | 43.6% | 41.7% |
| Free-cash-flow margin | 36.5% | 9.7% | 37.5% | 6.9% | 58.3% | 19.0% | 15.1% |
| Free-cash-flow margin, 3-year average | 39.0% | 23.6% | 47.6% | −10.1% | 59.7% | 20.4% | 19.1% |
| Stock pay / revenue | 1.5% | 2.1% | 2.5% | 1.6% | 2.0% | 1.8% | 1.6% |
| Change in share count | 5.7% | 6.1% | 7.4% | 29.5% | 23.8% | 5.9% | 6.1% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 23.9% | 15.0% | 4 of 17 |
| Change in growth rate Growth | +6.9pp | +1.1pp | 2 of 17 |
| Net margin Profitability | 38.6% | 7.8% | 4 of 17 |
| Stock pay as % of revenue Cash generation | 1.5% | 1.8% | 6 of 16 |
| Change in share count Balance sheet | 5.7% | 6.1% | 7 of 17 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Line of business | Revenue | YoY |
|---|---|---|
| Senior Housing Operating Portfolio | $80.1M | ▲ 47.1% |
| Real Estate Investment | $0 | — |
These categories overlap or exclude eliminations, so shares aren't shown.
From National Health Investors Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $666M | 8.7M | 22.9% | ▲ 81.7% |
| Vanguard Portfolio Management LLC | $353M | 4.6M | 12.1% | ▲ 11.8% |
| State Street Corp | $211M | 2.7M | 7.2% | ▲ 38.6% |
| Vanguard Capital Management LLC | $160M | 2.1M | 5.5% | ▲ 0.7% |
| Principal Financial Group Inc | $151M | 2.0M | 5.2% | ▲ 16.2% |
| Bank Of New York Mellon Corp | $123M | 1.6M | 4.2% | ▲ 212.1% |
| Geode Capital Management, LLC | $107M | 1.4M | 3.7% | ▲ 7.0% |
| Bank Of America Corp | $77.7M | 1.0M | 2.7% | ▲ 2.7% |
| Charles Schwab Investment Management Inc | $67.1M | 880K | 2.3% | ▲ 6.6% |
| Nomura Asset Management International Inc. | $66.4M | 870K | 2.3% | ▼ 3.0% |
| Dimensional Fund Advisors LP | $51.5M | 676K | 1.8% | ▼ 1.5% |
| Norges Bank | $51.3M | 672K | 1.8% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not National Health Investors Inc's complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Mccabe Robert A Jr Director | June 15, 2026 | Buy | 890 | $71.65 | $63,769 |
| Mendelsohn D. Eric CEO and President | June 5, 2026 | Buy | 1,500 | $68.84 | $103,260 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
In the last 12 months, 1 member of Congress disclosed 2 purchases and 0 sales of National Health Investors Inc shares.
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
